Global Multistakeholder Panel Provides First-of-its-Kind Guidance on Assessing the Value of Biosimilar Drugs
ISPOR—The Professional Society for Health Economics and Outcomes ResearchISPOR—The Professional Society for Health Economics and Outcomes Research published a new ISPOR Report that provides an overview of gaps and challenges in the value assessment of biosimilars and identifying potential approaches to address them. The report was published in the August 2023 issue of Value in Health.